Program evaluations can play an important role in formulating goals, objectives, and implementation strategies for a variety of planning activities throughout the Department of Health and Human Services (HHS). Program evaluations also tell us whether our efforts are successful. While there are still gaps in what we know, we now are beginning to as
In some cases, achieving our strategic goals and objectives may be impeded by factors that are beyond the control of the Department of Health and Human Services (HHS). For example, national or local economic conditions can influence whether we are successful in helping families on welfare become economically independent. In some cases, there may b
Many programs within the Department have goals, objectives, and target populations that appear similar. Likewise, many Department programs appear to duplicate or overlap programs in other Federal agencies. Many state, local, and private sector programs also have goals, objectives, and target populations in common with Department programs. Because
From a privacy-protection perspective, there is a very wide distinction between personally identifiable data and truly anonymized data . But in practice the demarcation between these extremes is not sharp. Attending assiduously to where particular data lie on the spectrum between them, and especially to data that are somewhere in the middle, i
Obviously some kinds of data are felt by data-subjects or the public in general to be especially sensitive. A commonly cited example is that HIV–AIDS data are much more sensitive than, say, data about wrist fracture. Whether sensitivity is somehow justified will always be debatable within the context. But for purposes of ethical practices, polic
Versions of an omnibus "Medical Records Confidentiality Act" are being considered by the U.S. Congress, as is a "Genetic Confidentiality and Discrimination Act." Some States are revising their medical-privacy laws covering information on mental health, HIV–AIDS status, or genetics. All of these will have implications for research.
As illustrated in the "Big Pharm Cold Start" scenario, the prospects of developing a new medication for cocaine abuse and taking it through a full product development cycle do not appear favorable given a moderate wholesale price comparable to LAAM ($2.50 per patient per day) and what amounts to an optimistic target market of 125,000 patients (i.e
In this scenario, a large pharmaceutical company takes on the full product development cycle, i.e., a "cold start" with preclinical discovery and research. The new Product A will require about $150 million in uncapitalized expenditures to develop and will be ready for launch following FDA approval in 13 years. The company anticipates securing a pa
In addition to changing behavior and reducing environmental health risks, improving health in the United States involves assuring that everyone has access to health care. The focus of Goal 3 is to promote increased access to health care, especially for persons who are uninsured, underserved, or otherwise have health care needs that are not adequat
How We Will Accomplish Our Objective
We will provide financial and technical assistance to a variety of community prevention services. Our priorities include:
comprehensive state programs for the prevention of sexually transmitted diseases (STDs).
Research indicates that a significant percentage of premature mortality and morbidity in the United States can be prevented if individuals avoid certain high-risk behaviors (e.g., smoking), adopt healthy ones (e.g., exercise), and reduce exposure to major environmental risks to health (e.g., lead-based paint). The strategic objectives under this g